Cite
HARVARD Citation
Han, T. et al. (n.d.). CYP3A‐Mediated Drug–Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody−Drug Conjugate, in Patients With CD30‐Positive Hematologic Malignancies. Journal of clinical pharmacology. pp. 866-877. [Online].